
Experience
MannKind to Acquire scPharmaceuticals for up to $360 Million
August 25, 2025
Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million
Related contacts
Related Practices & Industries
Blue Owl Capital Invests up to $262.5 Million in ITM Isotope Technologies Munich SE
May 27, 2025
Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.
Related contacts
Related Practices & Industries
Nuvation Bio Announces up to $250 Million Nondilutive Financings From Sagard Healthcare Partners
February 18, 2025
Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.
Related contacts
Related Practices & Industries
Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors
Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors
November 7, 2024
Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.
Related contacts
Related Practices & Industries
Cooley Advises Uber on $5 Billion Investment-Grade Revolving Credit Facility
October 2, 2024
Cooley advised Uber Technologies on its $5 billion investment-grade revolving credit facility.